Docon Technologies Private Limited has announced the release of a pledge on 1,75,00,000 equity shares of Thyrocare Technologies Limited. These shares, representing 10.99% of the total equity, were held by Docon as promoter. The pledge was created in favour of Catalyst Trusteeship Limited as security for Non-Convertible Debentures issued by API Holdings Limited, Docon’s holding company. The release occurred on August 11, 2026.
Pledge on Thyrocare Shares Released
Docon Technologies Private Limited (Docon), a promoter of Thyrocare Technologies Limited (Thyrocare), has confirmed the release of a pledge on 1,75,00,000 equity shares of Thyrocare. These shares constitute approximately 10.99% of the total equity share capital of Thyrocare. The pledge was initially placed in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, to secure the existing Non-Convertible Debentures (NCDs) issued by API Holdings Limited, Docon’s holding company.
Details of the Release
The release of this pledge was executed on August 11, 2026. Prior to this release, Docon’s total shareholding in Thyrocare was 9,69,69,696 equity shares, representing 60.92% of the company’s total equity share capital, with 9,69,69,696 shares encumbered. Following the release, Docon’s total shareholding remains unchanged at 9,69,69,696 equity shares (60.92%), but the number of encumbered shares has reduced to 7,94,69,696 (49.93%). This action clarifies the encumbrance status of a significant portion of the promoter’s holding.
Source: BSE
